Data presented at this year?s American Association for Cancer Research (AACR) meeting show that Merck KGaA?s targeted cancer therapy Erbitux? (cetuximab) significantly prolongs progression-free survival and increases overall response rate in metastatic colorectal cancer patients.
Indian government committed to providing second-line drugs free of cost to people who develop resistance to the existing treatment for HIV /AIDS.
Reclast? (zoledronic acid) has received US regulatory approval as the first new treatment in nearly a decade for patients with a bone condition known as Paget’s disease, estimated to affect about one million people in the US alone.
Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.
Access to antiretroviral therapy for advanced HIV infection in low- and middle-income countries continued to grow throughout 2006, with more than two million people living with HIV/AIDS receiving treatment in December 2006, a 54 per cent increase over the 1.3 million people on treatment one year earlier in these countries.
More than two million people in low- and middle-income countries now receive HIV therapy. Efforts must increase significantly to increase access to HIV treatment and prevention.
According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI?) ? a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) ? also reduces vision loss in patients with relapsing MS.
A consortium of Canadian and American researchers report in Nature Genetics the results from a search of the entire human genome for genetic risk factors leading to the development of Crohn’s disease.
A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.
In a clinical trial testing two different ways to treat Helicobacter pylori infection (a common cause of stomach ulcers), researchers found that four antibiotics given sequentially cured the infection more often than standard treatment with three antibiotics taken together for 10 days.